协和医学杂志

2018, v.9(01) 60-68

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

黑色素瘤的生物标志物:从基因组学到表观遗传学
Biomarkers of Melanoma: from Genetics to Epigenetics

吴海竞;付思祺;李倩文;张慧明;陆前进;郭重;
WU Hai-jing;FU Si-qi;LI Qian-wen;ZHANG Hui-ming;LU Qian-jin;GUO Zhong;Department of Dermatology,Second Xiangya Hospital,Central South University,Hunan Key Laboratory of Medical Epigenomics;Program in Dermatopathology,Harvard Medical School;Department of Pathology,Brigham and Women' s Hospital,Harvard Medical School;

摘要(Abstract):

黑色素瘤是一种发病率极高、极难治愈的皮肤恶性肿瘤,其中转移性黑色素瘤的5年生存率几乎为零。虽然化疗和免疫疗法(如抗PD-1/PD-L1单克隆抗体生物制剂)发展迅速,药物抵抗的高发率仍是治愈率低的主要问题。因此,目前研究热点逐渐转移至"运用生物标志物进行早期辅助诊断和药物反应预测"。随着检测技术的日新月异,很多新型生物标志物被发现,甚至已作为治疗靶点。本文从基因水平和表观遗传学水平总结黑色素瘤的生物标志物研究进展,并讨论其对疾病诊断、发展和治疗反应的预测价值,为寻找潜在治疗靶点提供新的思路。
Melanoma is one of the most aggressive cutaneous malignancies with an increasing incidence in recent decades,especially in western countries. It is considered to be an incurable disease,and patients with metastatic melanoma survive no more than 5 years. Despite rapid improvement in chemotherapy and immunotherapy,such as anti-PD-1/PD-L1 treatment,the high frequency of drug resistance remains a difficult problem. Thus,recent research has shifted slightly to the field of biomarkers to achieve the more urgent goal of aiding in the diagnosis and predicting response and resistance to therapy. With the development of fascinating technologies in laboratory testing,numerous novel biomarkers have been identified,and some of them exhibit potential as therapeutic targets.In this review,we summarize the latest genetic and epigenetic biomarkers,discuss their role in the prediction of disease progression and response to therapies,and provide insights into potential targets for future therapies.

关键词(KeyWords): 黑色素瘤;PD-1;5-羟甲基化胞嘧啶;微小RNA;长链非编码RNA
melanoma;PD-1;5-hydroxymethylated cytosine;micro-RNA;long non-coding RNA

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81220108017;81522038;81602767;81430074);; 湖南省杰出青年基金(2013FJ4202);; 湖南省青年基金(2017JJ3453)

作者(Author): 吴海竞;付思祺;李倩文;张慧明;陆前进;郭重;
WU Hai-jing;FU Si-qi;LI Qian-wen;ZHANG Hui-ming;LU Qian-jin;GUO Zhong;Department of Dermatology,Second Xiangya Hospital,Central South University,Hunan Key Laboratory of Medical Epigenomics;Program in Dermatopathology,Harvard Medical School;Department of Pathology,Brigham and Women' s Hospital,Harvard Medical School;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享